Tag: ImmunityBio

ImmunityBio, a biotechnology firm, has unveiled staggering commercial growth for its cancer therapy ANKTIVA. The company's fiscal 2025 performance was ...

ImmunityBio has achieved a significant regulatory milestone in Europe, securing conditional marketing authorization from the European Commission for its therapy, ...

ImmunityBio has initiated a new clinical study, marking a strategic expansion of its development pipeline. The U.S. biotechnology firm announced ...

ImmunityBio has entered February with significant operational momentum, driven by surging revenue, greater clarity from U.S. regulators, and initial international ...

ImmunityBio has entered 2026 with significant momentum, propelled by a confluence of fresh clinical data, key regulatory communications, and international ...

The biotech sector is witnessing a remarkable event as ImmunityBio experiences a parabolic rally to begin the year. This surge ...

A convergence of robust clinical data, explosive revenue growth, and a key international regulatory approval has propelled ImmunityBio's stock to ...

The biotechnology sector has a new standout performer, with ImmunityBio capturing significant investor attention. While numerous pharmaceutical stocks continue to ...

The biotechnology sector is demonstrating its notoriously unforgiving nature, with ImmunityBio caught in a severe downturn. As the company's stock ...

ImmunityBio finds itself at a pivotal moment, with groundbreaking clinical achievements coinciding with significant financial improvements. The biotechnology firm's recent ...